# Retatrutide Research: Phase 1, 2, and 3 Trial Record with Citations > Retatrutide research summary: Phase 1b pharmacokinetics (~6-day half-life), Phase 2 obesity (-24.2% body weight, 48 wks), T2D, MASLD, and body-composition data. All claims cited to source. Every figure attributed. Every gap marked. Phase 1b through the TRIUMPH Phase 3 program. ## The short version — the retatrutide research in plain English Retatrutide is an experimental drug (LY3437943) made by Eli Lilly that targets three hormone receptors at the same time. Think of hormones as chemical signals the body uses to manage hunger, blood sugar, and how much energy it burns. Retatrutide imitates three of those signals at once — GLP-1 (which reduces appetite and helps control blood sugar), GIP (which boosts insulin release after meals and affects fat tissue), and glucagon (which raises the amount of energy the body burns at rest). In trials, this triple action produced larger weight reductions than drugs targeting only one or two of these receptors. The Phase 1 study established that the drug stays in the body for about six days after each injection, which is why it is given once a week. Phase 2 trials in people with obesity and in people with type 2 diabetes found meaningful reductions in body weight, blood-sugar markers, and liver fat. Phase 3 trials are now running. The drug is not approved anywhere yet. ## How does retatrutide work — mechanism of action Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid acylation that binds albumin in the bloodstream and extends its circulating half-life. It is a simultaneous agonist at three class-B GPCRs (G-protein-coupled receptors — a family of cell-surface proteins that relay hormone signals into cells): - **GLP-1R (GLP-1 receptor):** Appetite suppression; glucose-dependent insulin secretion; slowing of gastric emptying. - **GIPR (GIP receptor):** Insulinotropic amplification; adipose (fat tissue) effects including fat-cell differentiation and energy storage. - **GCGR (glucagon receptor):** Increased resting energy expenditure; hepatic lipid metabolism — the breakdown of fat stored in the liver. Cryo-EM structural studies resolved retatrutide binding simultaneously at all three receptors at resolutions of 2.68/3.26/2.84 Å, confirming true tri-agonism rather than sequential or partial activation [3]. Relative potency versus native hormones: approximately 8.9x at GIPR, 0.3x at GCGR, 0.4x at GLP-1R [3]. This potency profile — GIPR-dominant, with controlled glucagon activation — is the engineered basis for combining appetite suppression and energy expenditure without the dysglycemia risk that would arise from unconstrained glucagon activity. The 2025 Biomolecules review characterized this architecture as a step-change in anti-obesity pharmacology, with the glucagon arm's energy-expenditure contribution distinguishing retatrutide from dual GIP/GLP-1 agonists [6]. ## Retatrutide vs tirzepatide — what the comparative record shows No head-to-head randomized controlled trial of retatrutide versus tirzepatide (another dual GIP/GLP-1 agonist, currently approved for obesity and type 2 diabetes) has reported results as of mid-2026. An active-comparator Phase 3 trial is listed among the TRIUMPH trials. Cross-trial comparisons are confounded by different study designs, populations, and durations and must be interpreted with care. From the available trial records: retatrutide at 12 mg/48 weeks in the Phase 2 obesity trial produced a mean -24.2% body-weight change [1]. The 2026 multi-receptor agonist review characterizes retatrutide (20-24% weight reduction) and other next-generation agents as the most promising approach to a class-level limitation: substantial weight regain after discontinuation of GLP-1-based therapy [13]. The key mechanistic difference is the addition of glucagon-receptor agonism, which adds energy expenditure to the appetite-suppression and insulin-sensitization effects shared with dual agonists [6]. Until the active-comparator Phase 3 data are published, any superiority claim is extrapolation. ## Phase 1b pharmacokinetics and first-in-human findings The Phase 1b multiple-ascending-dose trial enrolled 72 adults with type 2 diabetes (HbA1c 7.0-10.5%). Doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly were studied over 12 weeks [4]. Key pharmacokinetic (drug-behavior) finding: half-life approximately 6 days, supporting once-weekly subcutaneous dosing. The highest-dose group showed a placebo-adjusted weight change of -8.96 kg (90% CI: -11.16 to -6.75 kg) over 12 weeks. Daily average glucose fell by -2.8 mmol/L at the 3 mg dose. Treatment-emergent adverse events were reported in 63% of participants, predominantly GI. The safety profile was characterized as acceptable; no severe hypoglycemia was recorded. ## Phase 2 efficacy: obesity, type 2 diabetes, MASLD **Obesity (48-week trial; n = 338):** Doses of 1, 4, 8, 12 mg once weekly versus placebo. Primary outcome: body-weight change at 48 weeks. Results: -24.2% (12 mg) vs -2.1% (placebo) [1]. GI adverse events dose-related and mostly mild-moderate; dose-dependent heart-rate increase peaking at 24 weeks; 18% discontinuation rate at 12 mg, primarily GI-driven. **Type 2 diabetes (36-week trial; n = 281):** Dose escalation from 0.5-12 mg once weekly versus placebo and active comparator. At 24 weeks: HbA1c -2.02% (12 mg) vs -0.01% (placebo). At 36 weeks: body weight -16.94% (12 mg) vs -3.00% (placebo) [2]. Mild-moderate GI AEs in 35%; no severe hypoglycemia; no deaths. **MASLD substudy (48-week; n = 98, ≥10% liver fat by MRI-PDFF, no T2D):** Liver fat change at 24 weeks: -82.4% (12 mg) vs +0.3% (placebo); 86% of participants at 12 mg reached normal liver fat content (<5%). Reductions sustained at 48 weeks: -86.0% at 12 mg [5]. **Body-composition substudy (T2D Phase 2; DXA):** Dose-dependent reductions in total fat mass with expected proportional lean-mass change [7]. Absolute lean-mass reduction is clinically meaningful at rapid-loss rates, particularly in sarcopenic-risk populations. ## Phase 3 and ongoing trial program The TRIUMPH program encompasses obesity, type 2 diabetes, cardiovascular outcomes, chronic kidney disease (TRANSCEND-CKD, NCT05929066), and an active-comparator study versus tirzepatide. A dedicated cardiovascular outcomes trial (NCT06383390) is also running. The TRANSCEND-CKD trial design paper (2025) confirmed retatrutide's investigation in chronic kidney disease as a standalone endpoint — attenuation of urine albumin-to-creatinine ratio was observed in Phase 2 data [11][12]. A 2026 multi-omic study in preclinical models found retatrutide suppressed lipogenesis (fat production), enhanced fatty-acid oxidation and mitochondrial function, downregulated inflammatory and fibrotic pathways in white adipose tissue, and elevated the anti-inflammatory metabolite 15-HETE — an early molecular picture of how the compound reshapes metabolic tissue beyond weight loss itself [15]. Long-term cardiovascular and renal outcome trial data remain pending. --- A broadsheet record of the retatrutide trial literature — every figure dated to its study, every gap filed in plain ink, no clinic behind the masthead.